Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04539093 · ClinicalTrials.gov registry record

Endothelial Function in Mechanical Circulatory Support

A clinical trial, sponsored by Medical College of Wisconsin.

Completed
Registry status
1
Enrollment target

NCT04539093: Completed study, sponsored by Medical College of Wisconsin.

NCT04539093 is a clinical trial that has completed, run by Medical College of Wisconsin. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04539093 has completed, sponsored by Medical College of Wisconsin.

COMPLETED
Registry status
1 participants
Enrollment target

Study Summary

The pathophysiology of HF is highly variable, with overlapping pathogenic mechanisms that complicates any attempt to create a simple and unified conceptual model. Left ventricular (LV) ejection fraction (EF), assessed as the fraction of the end-diastolic volume that is ejected upon contraction, has been the cornerstone metric for characterization of LV systolic function in patients with HF. LVEF demonstrates a strong inverse relationship with clinical outcomes in HF in patients with reduced EF (HFrEF). Current management options for the treatment of HFrEF include medical management, mechanical circulatory support, and cardiac transplantation. In the setting of refractory end stage HFrEF, the standard of care is heart transplantation. Since limited organ procurement is a significant constraint to the treatment of patients with advanced disease, durable mechanical circulatory support (MCS) with left ventricular assist devices (LVAD) were developed as a safe and efficacious treatment strategy for patients with advanced HF that is refractory to medical therapy. The advances in LVAD engineering and design, tailored towards defined physiological goals, have resulted in the creation of much smaller continuous-flow (CF) pumps that possess technical superiority, pump durability, and ease of implantation compared to the older and larger pulsatile-flow pumps. The addition of speed modulation algorithms to the next generation centrifugal CF LVADs, has decreased the incidence of device related adverse events. Our interest lies in the impact of continuous flow hemodynamics on endothelial function and the cardiac and end-organ responses to this novel therapy. Current knowledge of the impact of these specific advances in LVAD therapy is however limited by the relative youth of the field. Thus, the goal of this research project is to study human LVAD patients and to determine the impact of speed modulation algorithms in CF physiology on microvascular and endothelial function and i

Primary Outcome

Measurement of blood nitric oxide levels will be used to evaluate vascular endothelial function. Flow-mediated dilation technique will then be used as a barometer of nitric oxide availability. The concentration of nitric oxide levels and degree of flow-mediated dilation would correlate with endothelial function.

Interventions

  • OTHER Exposure of interest - Use of left ventricular assist device (LVAD)

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2022-01-01
Est. Completion 2022-11-11
Medical College of Wisconsin

447 total trials

What the finished NCT04539093 record still lists

NCT04539093 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Exposure of interest - Use of left ventricular assist device (LVAD) is the first listed.

NCT04539093 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04539093 about?

NCT04539093 is a clinical study titled "Endothelial Function in Mechanical Circulatory Support". The pathophysiology of HF is highly variable, with overlapping pathogenic mechanisms that complicates any attempt to create a simple and unified conceptual model. Left ventricular (LV) ejection fraction (EF), assessed as the fraction of the end-diastolic volume that is ejected upon contraction, has ...

What is the current status of trial NCT04539093?

This trial is currently completed. The enrollment target is 1 participants. The study started on 2022-01-01. Estimated completion is 2022-11-11.

What interventions are being tested in trial NCT04539093?

The interventions under investigation include: Exposure of interest - Use of left ventricular assist device (LVAD) (OTHER).

Who is sponsoring clinical trial NCT04539093?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04539093, the US trial registry maintained by the National Library of Medicine. NCT04539093 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.